Nutrizym as a pancreatic enzyme replacement by Moshal, M.G.
20 July 1974 S.A. MEDICAL JOURNAL 1489
Nutrizym as a Pancreatic Enzyme Replacement
M. G. MOSHAL
TABLE I. PANCREATIC FUNCTION
Stool Fat Excretion
Clinical Findings
Tube test secretin 1 U/kg intravenously; CCK·PZt 1.5 U/kg intra·
venously 1 h later.















While on placebo, mean (± SD) stool fat excretion in
the 20 trial patients was 27,6 ± 18,3 g/24 h. The lowest
stool fat excretion in any patient was 6,9 g/24 h. While on
Nutrizym mean faecal fat excretion was 12,4 ± 9,9 g/24 h.
The reduction of stool fats while on Nutrizym was highly
ignificant when analysed by paired f-tests (P<O,OOl).
Half the patients excreted less than 7 g/24 h while on
Nutrizym, and the remaining IQ showed significant
reductions.
/ ml. Normal val ues for 40 control subjects were: mean
total volume 156,6 ± 36,6 ml (P<O,OOl); mean bicarbo-
nate 83,6 ± 30,4 mEq /litre (P<O,OOl) and amyla.se in PZ
collection 9,9 ± 4,6 ,uU /ml (P<O,OOl) (P-values refer to
differences from the 20 patients with bicarbonate in 52
collection).
All patients on Nutrizym reported an improvement
in their stools. Three patients became constipated. When
the amount of Nutrizym was reduced, constipation disap-
peared, and patients were able to 'titrate' the dose of
Nutrizym on some occasions. The daily dose of 3 tablets
f.d.s. was only required in severe pancreatic insufficiency,




was 81 ± 44,6 m!. The mean bicarbonate in the 20 - 60
min collection after secretion (± SD) (52) was 45, I ±
27.2 mEq/litre. The mean amylase in the first 20 min
collection after CCK-PZ (± SD) (PZ) was 1,4 ± 1,3 flU
SUMMARY
Twenty courses of Nutrizym or placebo were administered
to patients with steatorrhoea due to pancreatic insuffi-
ciency. Stool fat excretion fell significantly in all patients
while on Nutrizym (P<O,OOl). On placebo, a mean (±SO)
of 27,6 ± 18,3 g/24 h of fat was excreted in the
stools. On Nutrizym a mean of 12,4 ±9,9 g/24 h of fat
was excreted. All patients felt subjectively better and
weight loss was arrested.
RESULTS
METHOD
S. At,.. Med. l., 48, 1489 (1974).
A double-blind therapeutic trial was carried out to assess
the efficacy of a powerful enzyme replacement therapy
in patients with proved pancreatic insufficiency. All
patients had increased stool fats. Nutrizym contains a
greater content of trypsin, lipase and amylase than plain
pancreatin, and has in addition two other advantages
over other enzyme replacements, namely ox bile and
peptidases. '
Pancreatic Function Tests
Twenty patients (17 male) with pancreatic insufficiency
and steatorrhoea were studied. Eighteen patients had
ethanol-induced chronic pancreatitis; 1 had an impacted
gallstone in a pouch at the ampulla of Vater; and 1
patient had a carcinoma of the pancreas. Ages ranged
from 22 to 65 years (mean 42,9, SD ± 10,6 years).
Forty courses of therapy were given in a double-blind
randomised cross-over fashion, consisting of Nutrizym
(E. Merck) 3 tablets f.d.s. for 4 weeks, or placebo. at the
same dosage. Twelve patients received placebo first, and
8 patients received Nutrizym first.
Fifteen patients had pancreatic function tests after
intubation, with secretin (Jorpes) 1 unit/kg intravenously
followed 1 hour later by CCK-pancreozymin (Jorpes)
1,5 units/kg intravenously; with measurements of volume,
amylase' and bicarbonate (van Slyke's method). Five
patients had pancreatitis demonstrated at laparotomy.
All patients had their faecal fat excretion' measured
over 72 hours during the last week of each course of
Nutrizym or placebo therapy.
All 15 patients tested had abnormal pancreatic function
tests (Table I). The mean total volume in 80 min (± 5D)
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DISCUSSION
N utrizym contains an inner core of pancreatic enzyme.
containing 2 500 units trypsin, 8 100 units lipase and
18000 units amylase.' This is approximately double the
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Fig. 1. Stool fat excretion in 20 trial patients.
value of Pancrex V Forte.' The core is enteric-coated.
Surrounding this is a shell of bromelains-a mixture of
proteolytic enzymes derived from the stem of the pine-
apple. The bromelain shell has been shown to produce
a significant increase in protein digestion.' Nutrizym,
therefore, offers a unique 'two-stage' combination of
activities. The proteolytic enzymes in the bromelain shell
are released in the stomach and initiate protein digestion.
The enteric-coated core then passes into the small intes-
tine where the ox bile and pancreatin are liberated, at twice
the enzyme concentration of other products.'
The present double-blind cross-over trial in 20 patients
has confirmed the effectiveness of Nutrizym in reducing
faecal fat excretion even when grossly raised, in patients
with pancreatic insufficiency. All patients felt a marked
improvement in their symptoms while on Nutrizym, and
there were no side-effects in this trial. Weight gain was
not significant in the short term, but there was an arrest
in the weight loss in 14 patients. Over a longer period,
after cessation of the trial, there was a slow gain in
weight in 19 of the patients, and the weight remained
constant in the remaining patient.
In a study to compare the effectiveness of Nutrizym
with that of Pancrex V Forte,' Nutrizym was shown to be
clearly superior. In vitro tests have demonstrated that
Nutrizym is the most effective of 20 compounds tested.'
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